UK: Hybrid Closed-Loop Insulin Improves Glycemic Control in T1D-Complicated Pregnancy

For pregnant women with type 1 diabetes, hybrid closed-loop insulin therapy significantly improves maternal glycemic control, according to a study published online Oct. 5 in the New England Journal of Medicine to coincide with the annual meeting of the European Association for the Study of Diabetes, held from Oct. 2 to 6 in Hamburg, Germany.

Tara T. M. Lee, M.B., B.S., from the Norfolk and Norwich University Hospitals NHS Foundation Trust in the United Kingdom, and colleagues conducted a multicenter trial involving 124 pregnant women with type 1 diabetes and a glycated hemoglobin level of at least 6.5 percent who were randomly assigned to receive standard insulin therapy or hybrid closed-loop therapy; both groups used continuous glucose monitoring. The percentage of time in the pregnancy-specific target glucose range (63 to 140 mg/dL), as measured from 16 weeks of gestation to delivery, was the primary outcome.

Source: Advances and More licensed by HealthDay